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SUMMARY – Ocular symptoms are regularly observed in patients with cavernous sinus dural arte-
riovenous fistulas (cDAVF). We aimed to evaluate the long-term efficacy and safety of endovascular 
approaches in patients with cDAVF presenting with different ocular symptoms. In a prospective 
study between June 2008 and March 2013, 46 patients with ocular symptoms due to cDAVF who 
were not eligible for conservative therapy, met the inclusion criteria and underwent endovascular 
treatment. They underwent a transarterial approach with histoacryl glue injections or transvenous 
coil embolization, all in one session. They were followed up for a mean period of 17.3 months (range 
7 to 30 months) clinically and using angiography. The mean age of patients was 36.8 years (18-60) 
and 65% of them were male. All patients showed venous drainage into the superior and inferior 
orbital veins. Access to the cavernous sinus was transvenous in ten patients, transarterial in 26 
patients, and mixed in ten patients. Initial symptoms were improved in 97.8% of patients and did 
not recur during the study follow-up. The procedural complications included: blurred vision, tran-
sient sixth nerve palsy and exacerbation of chemoproptosis in two, one and two patients respectively 
that completely resolved in initial weeks with no recurrence. No patient worsened or developed new 
symptoms suggestive of a recurrent fistula during the follow-up period. One patient experienced 
intracranial dissection of the internal carotid artery and ischemic stroke with an unfinished pro-
cedure. The relief of early presentation was durable in long-term follow-up and the cured lesions 
were stable in angiographic controls. Favorable and durable outcomes could be obtained following 
endovascular approaches for cDAVF presenting with different ocular symptoms.
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Introduction
Dural arteriovenous fistulas (DAVFs) account 
for 10%-15% of intracranial arteriovenous mal-
formations, and the presence of a dural arterial 
supply and the absence of a parenchymal nidus 
differentiate them from parenchymal or pial 
arteriovenous malformations 1. DAVFs occur 
in the transverse, sigmoid, and cavernous si-
nuses and most of them present in adulthood 2,3.
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All participants underwent examination by 
an ophthalmologist before treatment, and oph-
thalmic symptoms included chemosis, proptosis, 
eye redness, and blurred vision. Participants 
also reported having pulsatile tinnitus. Objec-
tive tests of visual acuity and visual fields were 
performed to provide baseline data for compari-
son after the endovascular procedure and dur-
ing follow-up monitoring. Vascular risk factors 
included hypertension (receiving medication for 
hypertension or blood pressure >140/90 mm Hg 
on repeated measurements), diabetes mellitus 
(receiving medication for diabetes mellitus or 
fasting blood glucose level ≥126 mg/dl), dyslipi-
demia (receiving lipid-lowering agents or having 
an overnight fasting cholesterol level >200 mg/
dl and low-density lipoprotein (LDL) > 100 mg/
dl), current cigarette smoking (current smok-
ers or those who quit smoking <6 months). A 
skilled neuroradiologist explained the benefits 
and potential risks of the endovascular therapy 
to the participants. The primary endpoint of the 
current investigation was the clinical and an-
giographic outcome of these patients after un-
dergoing endovascular interventional therapy. 
Procedures and Approaches
Patients were eligible for endovascular ther-
apy only if conservative therapy was not suit-
able or if there was no other therapeutic op-
tion of acceptably low risk. The imaging results 
available for referred cases were reviewed by 
an interventional neuroradiologist at our insti-
tute before management decisions were made. 
We repeated angiography for several patients 
at our hospital before decisions could be made 
regarding management. The final decision to 
proceed with a transarterial or transvenous 
approach was made only after analysis of the 
clinical, imaging, and angiographic findings 
in each case. Patients who gave informed con-
sent were transferred to the angiography room 
provided they had no contraindications for en-
dovascular procedures (e.g., renal failure, co-
agulopathy, and contrast allergy). The patients 
underwent complete cerebral angiography, in-
cluding both ICA and ECA for cDAVFs, as well 
as bilateral vertebral injections for diagnosis 
and identification of all arterial supplies to the 
fistulas. All cases received endovascular treat-
ment with a transarterial or transvenous ap-
proach. Before intervention, the Borden classi-
fication 13 was used to classify fistulas based on 
their venous drainage: Type I, the dural arte-
rial supply drains anterograde into the venous 
Cavernous sinus DAVFs (cDAVFs) form 
through an abnormal arteriovenous commu-
nication between the dural branches of the in-
ternal and external carotid arteries (ICA and 
ECA, respectively) and the cavernous sinus 
4. They occur less frequently than transverse/
sigmoid sinus DAVFs and have a low risk 
of hemorrhage 5. Some alarming ophthalmic 
symptoms, such as ophthalmic proptosis, ex-
traocular muscle palsies, chemosis, visual loss, 
and diplopia, as well as intracranial bruits may 
develop in patients with cDAVF 6-8.
The main management approaches for 
cDAVFs have included observation, stereotac-
tic radiosurgery, intermittent manual com-
pression of the ICA, endovascular treatment 
(transarterial or transvenous embolization), 
and neurosurgery 9. Endovascular techniques 
are the most commonly used treatment for pa-
tients with symptomatic cDAVFs that do not 
spontaneously resolve. However, recent inves-
tigations have indicated that embolization of 
cDAVFs is not a thoroughly safe procedure and 
may also be related to temporary ophthalmo-
plegia 10-12. Not only are the surgical approaches 
difficult, but cDAVF embolization has a high 
rate of postoperative cranial nerve deficit and 
associated occlusion of the ICA 13. Here we re-
port our experience using transarterial, trans-
venous, or a mixed approach endovascular 
treatment in 46 cDAVF cases and describe the 
early and mid-term outcomes.
Methods
Patients and Methods
Between June 2008 and March 2013, 55 pa-
tients with suspected cDAVFs were referred by 
ophthalmologists to our institute and evalu-
ated. Of these patients, 46 were not eligible 
for conservative therapy, met the inclusion 
criteria for our study, and underwent endovas-
cular treatment. The inclusion criteria were 
the following: age between 18 and 65 years, 
ophthalmic symptoms suggestive of cavernous 
DAVFs, and positive computed tomography 
angiography findings. Patients who met these 
criteria and provided signed consent were in-
cluded in the study. Patients with a history of 
any cerebrovascular anomalies, concurrent in-
tracranial arteriovenous malformation or any 
cerebral aneurysm, space-occupying lesion, ca-
rotid surgery, stroke, or chronic disability were 
excluded. 
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cure group included the patients in whom all 
symptoms disappeared despite a persistent 
shunt. An anatomic cure was defined as the 
disappearance of all symptoms with the angio-
graphic demonstration of the obliteration of the 
fistula. During the follow-up period, clinical 
and angiographic assessments were attempted 
for all patients. The safety of these procedures 
was evaluated by the incidence of any proce-
dure-related complications, including any ad-
verse event during the procedure or within 30 
days afterwards. Demographic features, vas-
cular risk factors, arterial supply and venous 
drainage of fistula, presenting symptoms, end-
ovascular approach via artery or vein or mixed 
approaches, classification of lesions, follow-up 
outcomes, and complications were recorded by 
an expert neuro-interventionist. 
Results
Overall, 46 patients were evaluated. Patients’ 
mean age was 36.83 ± 11.63 (18-60) years, and 
men predominated (65%). Eye redness and 
chemosis were the most common presenting 
symptoms. Patient characteristics are summa-
rized in Tables 1-3. The mean interval between 
the onset of clinical symptoms and treatment 
of the fistula was 42 days (median, 25 days; 
range, 3-131 days). All patients showed venous 
drainage into the superior and inferior orbital 
veins, and all patients were treated in one ses-
sion. Transarterial access was achieved in 26 
patients (Table 1). Access to the cavernous 
sinus was transvenous in ten patients (Table 
2) and ten patients underwent the procedure 
by mixed access (Table 3). Embolization of the 
cavernous sinus was technically successful 
and led to complete closure of the fistulas in 
all cases. Mean duration of follow-up was 17.3 
months (range, 7-30 months). Borden type Ib 
was predominately seen in our cases (87%). 
Complications related to transarterial embo-
lization procedures occurred in two patients 
(4%), and there were no complications related 
to transvenous embolization procedures. Four 
(8.6%) patients developed complications after 
mixed approach embolization. 
Detailed examination revealed that ocular 
symptoms related to venous congestion (che-
mosis or proptosis) resolved completely in all 
affected patients except in two cases of tran-
sient exacerbation (cases 8 in Table 1 and 5 in 
Table 3) due to partial thrombosis during the 
procedure. For these cases, anticoagulant plus 
sinus; Type II, the dural arterial supply drains 
into the venous sinus, but high pressure in the 
sinus causes both anterograde drainage and 
retrograde drainage via subarachnoid veins; 
and Type III, the dural arterial supply drains 
retrograde into subarachnoid veins. The Bor-
den classification scheme further subclassifies 
fistulas as having blood supplied from a single 
artery (a) or multiple arteries (b).
A transarterial approach was used through 
the ICA or ECA and then the feeding arteries. 
If the transarterial approach failed to reach the 
target or remained incomplete, a transvenous 
approach was done via the superior ophthal-
mic vein (SOV) or inferior petrosal sinus (IPS). 
Once the cavernous sinus was reached, cathe-
terization and coil embolization of the compart-
ments with outflow to dangerous venous con-
nections to the ophthalmic vein branches were 
attempted. A transarterial approach was pre-
ferred if there was an accessible arterial sup-
ply. Transarterial procedures were performed 
with the patients under local anesthesia, and 
systemic heparinization was achieved during 
the procedures with heparin. The vascular 
anatomy was carefully examined prior to glue 
injections to identify potential external-to-in-
ternal carotid artery anastomoses and to avoid 
damage to the cranial nerve supply. The proce-
dure was completed as soon as a control angio-
gram revealed complete occlusion of the fistula. 
If a patient remained symptomatic after a 
transarterial procedure, transvenous coil em-
bolization was undertaken. The arteriovenous 
shunts were approached via the venous routes 
of the SOV or IPS, and the detachable coils were 
selected according to the volume of the cavern-
ous sinus. Patency of the ICA on the same side 
was checked frequently during intermittent in-
jection of the embolic material. The procedure 
was ended when a control angiogram showed 
that the fistula was occluded. 
Follow-up
All cases were followed up clinically (with 
detailed ophthalmologic examination) by out-
patient visit at one, three, six and 12 months 
after the endovascular procedure and yearly 
thereafter until termination of follow-up. The 
patients were additionally instructed to visit 
their physician as soon as possible if ophthal-
mological or neurological symptoms occurred, 
even if it was not time for a scheduled follow-
up. Outcomes were divided into two categories: 
clinical cure and anatomic cure. The clinical 
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One patient (case 14 in Table 1) had de-
creased visual acuity and blurred vision, but 
regained normal vision within a few days af-
ter the procedure was completed. Among the 
ten patients who underwent the mixed ap-
proach, one had an exacerbation of her chemo-
sis and proptosis (case 5 in Table 3) and one 
case had blurred vision (case 10 in Table 3) 
that resolved completely during the observa-
tion period. One patient (case 8 in Table 3) 
had sixth cranial nerve palsies that experi-
enced normalization during follow-up moni-
toring. One 60-year-old patient with a history 
of hypertension and diabetes (case 9 in Table 
antiplatelet therapy was begun and continued 
for six weeks until the symptoms were relieved 
and angiography was normal (Figure 1).
Another two cases (cases 14 in Table 1 and 
10 in Table 3) had transient decreased visual 
acuity and blurred vision, which improved 
spontaneously. One patient (case 8 in Table 3) 
had periprocedural transient diplopia (caused 
by sixth cranial nerve palsies), and one patient 
(case 9 in Table 3) experienced intracranial 
dissection of the ICA during the procedure and 
was affected by ischemic stroke. Overall, there 
were five transient complications (11%) and 
one permanent complication (2%).
Table 2  Summary of information in patients who underwent a transvenous approach with complications and follow-up results.
No. Age
(y)/sex
Signs & Symptoms
at Presentation
Borden
Lesion
Type
Arteries Veins Complications
& Treatment
F/U
(m)
Outcome
Angio-
graphic
Clinical
1 60/M Rt. eye  redness
& chemosis/
tinnitus
|b ICA/MMA Opht (S to Inf)/
IPS
– 15 AC SR
2 37/M Rt. eye redness
& chemosis/
tinnitus
|b ICA/APA Opht/IPS – 28 AC SR
3 22/M Rt. eye redness
& chemosis/
tinnitus
|b APA/ICA/
MMA
Opht (S to Inf)/
IPS
– 19 AC SR
4 25/M Bilat. eye redness
& chemosis
|b ICA/APA Opht (S )/IPS – 21 AC SR
5 60/M Lt. eye redness
& chemosis/
tinnitus
|b ICA/
recurrent
of foramen
rotundom
Opht (S to Inf) – 16 AC SR
6 30/M Lt. eye redness
& chemosis/
tinnitus
|b ICA/APA Opht (S to Inf)/
SPA
– 25 AC SR
7 23/F Lt. eye redness
& chemosis
Proptosis
|b ICA/APA Opht (S to Inf)/
IPS
– 14 AC SR
8 46/F Lt. eye redness
& chemosis/
Proptosis
|b ICA/APA/
MMA
Opht (S to Inf)/
IPS
– 16 AC SR
9 30/M Lt. eye redness
& chemosis/
Proptosis
|b ICA/MMA Opht (S to Inf) – 15 AC SR
10 41/M Lt. eye redness
& chemosis/
Proptosis/
tinnitus
|b APA/MMA Opht (S to Inf)/
IPS
– 21 AC SR
AC: angiographically cured (complete occlusion); AEA: anterior ethmoidal artery; APA: ascending pharyngeal artery; CS: cavernous sinus; 
F: female; FU: follow-up period of time; ICA: internal carotid artery; IPS: inferior petrosal sinus; Lt: left; M: male; MMA: middle menin-
geal artery; Opht (s to inf): ophthalmic vein (superior to Inferior); PEA: posterior ethmoidal artery; Rt: right; SPS: superior petrosal sinus; 
SR: symptom relief.
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least seven months after the last procedure. 
An anatomic cure was achieved in all cases. 
Clinical cure was observed in 40 of 45 cases 
(89%). No patient worsened or developed new 
symptoms suggestive of a recurrent fistula 
during the follow-up period. Except for case 9 
in Table 3, none of the patients had an occlu-
sion of the ICA, and no patient presented with 
symptoms of cerebral infarction in the follow-
up examination.
3) experienced intracranial dissection of the 
ICA during the procedure and subsequent is-
chemic stroke of left middle cerebral artery. 
The stroke regimen was immediately begun 
but she died three months into the follow-up 
period as a result of the stroke. Data from this 
patient were excluded from further analysis.
Forty-five patients (98%) experienced com-
plete obliteration of their cDAVFs as demon-
strated in follow-up angiograms obtained at 
No Age
(y)/sex
Signs
& Symptoms
at Presentation
Borden
Lesion
Type
Arteries Veins Complications
& Treatment
F/U
(m)
Outcome
Angio-
graphic
Clinical
5 42/F Lt. eye redness
& chemosis
|b ICA/APA Opht (S to Inf)/
IPS
– 21 AC SR
6 47/F Lt. eye redness
& chemosis
|b ICA/MMA Opht (S to Inf) – 26 AC SR
9 50/M Lt. eye redness
& chemosis/
blurred vision
|b ICA/APA Opht (S to Inf)/
IPS
– 19 AC SR
10 47/M Rt. eye redness
& chemosis/
blurred vision
|b ICA/MMA Opht (S to Inf)/
IPS
– 18 AC SR
13 30/F Lt. eye redness
& chemosis
|b APA/MMA Opht (S to Inf) Partial
thrombosis:
exacerbation
of chemosis
& proptosis/
anticoagulants
22 AC SR
during
6 weeks
22 19/M Lt. eye redness
& chemosis/
proptosis/
tinnitus/
Headache
|b APA/MMA Opht (S to Inf)/
IPS
– 16 AC SR
26 24/F Lt. eye redness
& chemosis/
proptosis
|b ICA/MMA Opht (S to Inf) – 12 AC SR
35 32/F Lt. eye redness
& chemosis/
tinnitus
|| ICA/APA/
MMA
Opht (S to Inf)/
IPS/
Sphenopalatine
Injury to cranial
nerve in CS:
Transient
6th nerve palsy/
conservative
17 AC SR
during
4 weeks
40 60/F Lt. eye redness
& chemosis/
proptosis
|b ICA/MMA Opht (S to Inf) ICA Dissection:
stroke 
– Flow
reduction
–
46 29/M Lt. eye redness
& chemosis/
proptosis
|b ICA/MMA Opht (S to Inf)/
IPS
Blurred vision/
conservative
16 AC SR
during
2 weeks
AC: angiographically cured (complete occlusion); AEA: anterior ethmoidal artery; APA: ascending pharyngeal artery; CS: cavernous sinus; 
F: female; FU: follow-up period of time; ICA: internal carotid artery; IPS: inferior petrosal sinus; Lt: left; M: male; MMA: middle menin-
geal artery; Opht (s to inf): ophthalmic vein (superior to Inferior); PEA: posterior ethmoidal artery; Rt: right; SPS: superior petrosal sinus; 
SR: symptom relief.
Table 3  Summary of information in patients who underwent a mixed transarterial and transvenous approach with complica-
tions and follow-up results.
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Figure 1  A 30-year-old man with chemosis and redness of left eye. Investigations including DSA showed dural AVF with supply 
from the left side external carotid artery. There was no accessory supply from the internal carotid or ascending pharyngeal arter-
ies (A- a and c) .The patient showed exacerbation of symptoms following transarterial occlusion of the fistula (B-a). He underwent 
medical treatment and showed a significant improvement a few weeks later (B-b).
A
a b c
a b
B
468
Long-Term Endovascular Treatment Outcome of 46 Patients with Cavernous Sinus Dural Arteriovenous Fistulas Presenting ... Ali Pashapour
anterior approach is beneficial because the pos-
terior part of the cavernous sinus can be em-
bolized first. Embolization of the posterior com-
partment of the cavernous sinus, where feeding 
arteries mainly occur, can reduce shunt flow 
and the risk of increasing venous pressure in 
most cases 24. We applied this method in our 
cases that underwent coil embolization. When 
dangerous and symptomatic venous drainage 
systems are occluded, the cavernous sinus can 
be embolized by placing the coils in the shunt-
ing portion. Compact packing of the cavernous 
sinus using coils should be avoided because the 
risk of cranial nerve deficit is high due to com-
pression of the nerves by the coils. Bink et al., 
in an investigation of 19 cDAVF patients with 
ophthalmologic complications, demonstrated 
that endovascular treatment via the trans-
venous approach through the IPS with detach-
able coils led to durable angiographic cDAVF 
closure and effective relief of symptoms. How-
ever, there was a 44% rate of ophthalmologic 
signs in long-term follow-up 18. Théaudin et al., 
in their study of endovascular treatment of du-
ral carotid-cavernous fistulas, demonstrated 
that complete occlusion of the fistula was ob-
tained in 87% of the patients treated via the 
transvenous approach, but only 25% of patients 
treated by the transarterial approach had the 
same outcome. Sixteen patients had early clini-
cal improvement after endovascular treatment. 
Cerebral hemorrhage occurred in one case af-
ter transvenous embolization. During follow-
up, cases treated by the transarterial route 
remained symptomatic, whereas 71% patients 
treated via the transvenous route were asymp-
tomatic 25. Our results from a single center expe-
rience of ten cases of transvenous cDAVF seem 
similar or superior to other series 8,15,26. This may 
be attributed to the vigilant detection and man-
agement of possible complications. However, the 
low number of our cases must be considered as 
well. The above results suggest that coil embo-
lization could be a stable and durable treatment 
for closure of cDAVF of the cavernous sinus.
Acrylic glue has been extensively used for 
transarterial embolization of intracranial 
DAVF, but there is no supportive evidence 
based on large series on its safety and effective-
ness 27,28. It is known that the material induces a 
typical sequence of thrombogenic events in the 
vessels (i.e., acute inflammation with mural an-
gionecrosis followed by chronic granulomatous 
vasculitis), leading to delayed occlusion of the 
shunt, which remains stable years after the em-
bolization procedure 29. Paredes et al., in a report 
Discussion
The linchpin of DAVF therapy is treatment 
via endovascular approaches 15,16, but the exper-
tise of a multidisciplinary team comprising an 
interventional neuroradiologist, neurosurgeon, 
neurologist, and an ophthalmologist is needed 
for optimal results. Before proceeding with 
any treatment, careful assessment of a patient 
should be conducted, including clinical presen-
tation; demographics; presence of comorbidi-
ties and their type, location, and classification; 
and the angiographic features of lesion 17. Most 
previous investigations did not focus on neuro-
ophthalmologic findings in detail or demon-
strate the overall clinical outcome in patients 
after endovascular treatment of cDAVF 18.
The current study shows the efficacy and du-
rability of endovascular embolization for cDAVF 
and significant regression of ophthalmologic in-
volvement in a series of 46 cases. We used tran-
sarterial glue embolization as the primary treat-
ment for intracranial DAVF due to its safety 
and effectiveness 19,20. This approach was applied 
in more than half (n = 26) of the cases, and it 
safely yielded successful results that extended 
through the follow-up period. In ten cases 
(21.7%) in which this approach was not possible 
or failed, transvenous access of the target sinus 
was done with successful results. We were able 
to achieve complete obliteration of the fistula 
in 100% of cases, with cure or improvement 
of symptoms in all cases on clinical follow-up. 
In some studies, transvenous embolization 
using coils for curative purposes has been dem-
onstrated to be very effective (complete occlu-
sion in 80%–100% of cases) or anatomic and 
clinical cure rates of 71%–89% and 77%–96% 
in cDAVF cases, respectively 8,21,22. However, 
serious complications associated with vascular 
damage and intracranial hemorrhage have also 
been reported 8,23. Insufficient embolization leads 
to a worsening of symptoms due to increased 
pressure in the venous system. Also, to achieve 
success, procedures must include a precise as-
sessment of diagnostic images and clinical con-
ditions 17. During the procedure, immediate oc-
clusion of cavernous sinus outlets to prevent 
drainage to dangerous venous systems should 
be done. Therefore, prior to coils being placed, 
it is important to evaluate the compatibility of 
the microcatheter with all outlets of the cavern-
ous sinus. Furthermore, the procedure should 
be done within the shortest possible time to 
prevent increased pressure in other drainage 
veins during embolization 6. In this regard, the 
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Zhang et al. reported a review of 22 patients 
with cDAVFs who were followed for a mean of 
21.6 months. Treatment was by transarterial 
Onyx embolization alone or transarterial and 
transvenous Onyx embolization. The research-
ers found successful obliteration of cDAVFs in 
91% of cases and complete embolization in 100% 
of them without any recurrence. After incom-
plete transarterial embolization in 9% of cases, 
however, symptoms recurred and transvenous 
embolization was repeated. Transient cranial 
neuropathy was seen in 18% of the patients 15.
Our experience with transarterial glue em-
bolization shows that it is an effective primary 
treatment for intracranial DAVFs. Further, it 
is a safe method of treatment when vascular 
anatomy is carefully considered. 
A noteworthy point of our study was the 
lower mean age of patients in comparison with 
other studies: this could be partly because the 
general population is young. Cosmetic appear-
ance is more important for young people, and 
they have a greater willingness to undergo 
treatment. 
In conclusion, early evidence indicated that 
endovascular management of cDAVF is safe 
and effective in achieving an initial angio-
graphic cure and a long-term clinical cure in 
patients who were not candidates for conserva-
tive therapy. Results of our series suggest that 
angiographic and clinical outcomes of endovas-
cular embolization remain relatively stable at 
midterm follow-up, but large series and long-
term investigations need to be designed.
of 81 patients, demonstrated that endovascu-
lar transarterial treatment of cDAVF achieved 
symptomatic improvement in 78% of patients, 
with a complication rate of 5% 16. By using tran-
sarterial glue embolization alone, we were able 
to achieve complete occlusion of the fistula in 
100% of cases, with cure or improvement of 
symptoms in 92% of cases on clinical follow-up. 
In addition, transarterial glue embolization 
was used in combination with transvenous 
approach coil embolization in ten other cases. 
In this approach, if the feeding artery is de-
rived from branches of the ECA, embolization 
is easily performed and can decrease shunt 
flow. Nonetheless, achieving a complete cure 
is complicated in some cases because of the 
recruitment of a blood supply from collateral 
arteries and difficulty in the catheterization 
of the feeding arteries 30. Therefore, a mixed 
approach of transarterial glue embolization 
and transvenous coil embolization is gener-
ally used in such cases to relieve symptoms. 
Our experience shows that glue emboliza-
tion is a safe method for the treatment of in-
tracranial cDAVFs. We had only one case in 
which a patient was affected by ICA dissec-
tion. Careful consideration of the anatomy in 
each patient allowed cranial nerve complica-
tions to be avoided in our series. To achieve a 
higher cure rate, use of the wedged microcath-
eter technique with a low-concentration glue 
may also establish flow arrest conditions in 
which permeation of the glue into the venous 
drainage occurs by a controllable route 31,32.
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